Rhumbline Advisers Reneo Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.51 - $1.9 $15,083 - $18,979	-9,989 Reduced 91.04%	983 $1,000
Q1 2024 May 09, 2024	BUY	$1.59 - $1.74 $607 - $664	382 Added 3.61%	10,972 $18,000
Q4 2023 Feb 08, 2024	SELL	$1.34 - $8.43 $991 - $6,238	-740 Reduced 6.53%	10,590 $16,000
Q3 2023 Nov 09, 2023	BUY	$5.44 - $8.13 $17,549 - $26,227	3,226 Added 39.81%	11,330 $86,000
Q2 2023 Aug 08, 2023	BUY	$5.44 - $10.5 $44,085 - $85,092	8,104 New	8,104 $53,000

31M

50.8K

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.